Stelfonta® — Tabasco’s Story
Control and Therapy Series · 03.01.2026 · 3-6
DOI: 10.30722/2v7hge35 ↗Kurz gefasst
Fachartikel in der Zeitschrift Control and Therapy Series, online erschienen am 03.01.2026. Verfasst von Christopher Simpson.
Abstract (Originalsprache)
An 11-year-old crossbred dog with a facial mast cell tumour was treated using intralesional tigilanol tiglate (Stelfonta®) after the owners declined surgery. Following careful preparation and management of mast cell degranulation risk, the tumour underwent expected necrosis and healed by secondary intention. The treatment was well tolerated and resulted in complete clinical resolution of the lesion, highlighting Stelfonta as a practical alternative to surgery for selected non-metastatic cutaneous mast cell tumours.
Zitieren
APA
Simpson, C. (2026). Stelfonta® — Tabasco’s Story. Control and Therapy Series, 3-6. https://doi.org/10.30722/2v7hge35
Vancouver
Simpson C. Stelfonta® — Tabasco’s Story. Control and Therapy Series. 2026:3-6. doi:10.30722/2v7hge35
BibTeX
@article{Simpson2026,
author = {Simpson, Christopher},
title = {Stelfonta® — Tabasco’s Story},
journal = {Control and Therapy Series},
year = {2026},
pages = {3--6},
doi = {10.30722/2v7hge35}
}
EUVIMED